Petri Bono
Overview
Explore the profile of Petri Bono including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
6722
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niemenoja O, Ammala A, Riihijarvi S, Lillrank P, Bono P, Taimela S
BMC Public Health
. 2024 Nov;
24(1):3100.
PMID: 39522046
Background: Most current studies on COVID-19 have focused on the first weeks or months of the pandemic or have addressed specific diseases. The long-term effects of the COVID-19 pandemic on...
2.
Niemenoja O, Ammala A, Riihijarvi S, Lillrank P, Bono P, Taimela S
BMC Health Serv Res
. 2024 Apr;
24(1):483.
PMID: 38637794
Background: COVID-19 has had wide-reaching effects on healthcare services beyond the direct treatment of the pandemic. Most current studies have reported changes in realised service usage, but the dynamics of...
3.
Rannikko J, Verlingue L, de Miguel M, Pasanen A, Robbrecht D, Skytta T, et al.
Cell Rep Med
. 2023 Dec;
4(12):101307.
PMID: 38056464
Macrophage Clever-1 contributes to impaired antigen presentation and suppression of anti-tumor immunity. This first-in-human trial investigates the safety and tolerability of Clever-1 blockade with bexmarilimab in patients with treatment-refractory solid...
4.
Rannikko J, Bono P, Hynninen J, Hollmen M
Cancer Immunol Res
. 2023 Nov;
12(1):48-59.
PMID: 37922365
Immune checkpoint inhibitors (ICI) show substantially greater efficacy in inflamed tumors characterized by preexisting T-cell infiltration and IFN signaling than in noninflamed "cold" tumors, which often remain immunotherapy resistant. The...
5.
Jones R, Fizazi K, James N, Tammela T, Matsubara N, Priou F, et al.
Prostate Cancer Prostatic Dis
. 2023 Oct;
27(4):786-789.
PMID: 37884613
Background: In patients with metastatic castration-resistant prostate cancer, darolutamide was well tolerated for 25 months, but minimal long-term safety data are available. Methods: Treatment-emergent adverse events (TEAEs) for patients receiving...
6.
Huuhtanen J, Kasanen H, Peltola K, Lonnberg T, Glumoff V, Bruck O, et al.
J Clin Invest
. 2023 Jan;
133(6).
PMID: 36719749
BackgroundRelatlimab plus nivolumab (anti-lymphocyte-activation gene 3 plus anti-programmed death 1 [anti-LAG-3+anti-PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on...
7.
Kankkunen E, Penttila P, Peltola K, Bono P
Acta Oncol
. 2022 Jul;
61(10):1240-1247.
PMID: 35905053
Background: There is an ongoing need to identify biomarkers for correct patient selection for immune-oncology treatments in metastatic renal cell carcinoma (mRCC). The aim of our study was to evaluate...
8.
Niemenoja O, Taalas A, Taimela S, Bono P, Huovinen P, Riihijarvi S
BMJ Open
. 2022 Feb;
12(1):e046490.
PMID: 35105608
Objective: To evaluate the trajectories of acute upper respiratory tract infections (URTIs), COVID-19, and the use of antibiotics in Finland during the COVID-19 epidemic. Design: Population-based cohort study. Setting: Electronic...
9.
Joensuu H, Kellokumpu-Lehtinen P, Huovinen R, Jukkola A, Tanner M, Ahlgren J, et al.
J Clin Oncol
. 2022 Jan;
40(10):1051-1058.
PMID: 35020465
Purpose: Few data are available regarding the influence of adjuvant capecitabine on long-term survival of patients with early breast cancer. Methods: The Finland Capecitabine Trial (FinXX) is a randomized, open-label,...
10.
Oudard S, Benhamouda N, Escudier B, Ravel P, Tran T, Levionnois E, et al.
Cells
. 2022 Jan;
11(1).
PMID: 35011579
The modulation of subpopulations of pro-angiogenic monocytes (VEGFR-1CD14 and Tie2CD14) was analyzed in an ancillary study from the prospective PazopanIb versus Sunitinib patient preferenCE Study (PISCES) (NCT01064310), where metastatic renal...